Clinical Trial

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

Study acronym: RAPAMALYMPH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-08-03; most recent amendment 2026-05-20.
Status change: Not Yet Recruiting → Recruiting 2018-10-12
Trial Details
NCT Number NCT03243019
Lead Sponsor University Hospital, Lille
Collaborators: Ministry of Health, France
Conditions Lymphatic Malformation, Pediatric
Enrollment 28 participants
Start Date 2018-06-25
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-22